ESTRO 2025 - Abstract Book

S233

Brachytherapy - Gynaecology

ESTRO 2025

The median follow-up time was 33 months, and the median external beam dose was 45 Gy. The median interval between the last external beam fraction and the first brachytherapy was 7 days, resulting in a median OTT of 50 days. A combined intracavitary/interstitial technique was used in 88% of cases, with a median high-risk clinical target volume dose (D90) of 90.5 Gy (see also table 2).

Complete remission was observed in 96% of patients after three months. The three-year overall survival rate was 74%, with 95% local control, 95% pelvic lymph node control, and 65% disease-free survival.